Compare Neurocrine Biosciences Inc (NBIX) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Riot Platforms Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Riot Platforms Inc trades at $21.85 (market cap $8.35B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| NBIX | RIOT | |
|---|---|---|
Market Cap | $15.77B | $8.35B |
Sector | Health | Technology |
52-Week High | $185.50 | $28.67 |
52-Week Low | $123.10 | $11.83 |
Enterprise Value | $15.78B | $8.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
RIOT Platforms trades at $22.26, up 2.11% today, with a bullish technical signal from moving averages. The stock shows strong analyst support with 94.7% buy ratings and a $33 consensus price target. Recent news highlights a transformative $9.1 billion AI data center deal with Anthropic, shifting focus from Bitcoin mining to high-margin AI infrastructure. However, fundamental challenges persist with negative net income margins and consecutive earnings misses.
The outlook balances significant AI-driven growth potential against current profitability concerns. The Anthropic partnership provides long-term revenue visibility but execution risks remain. With the stock trading near analyst price targets, upside depends on successful AI transition and improved financial performance. Key risks include competitive pressures, regulatory uncertainty, and continued cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
